Nicholas R Rydzewski
Overview
Explore the profile of Nicholas R Rydzewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
119
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
2.
Rydzewski N, Dinakaran D, Zhao S, Ruppin E, Turkbey B, Citrin D, et al.
NEJM AI
. 2024 Aug;
1(5).
PMID: 39131700
Background: As artificial intelligence (AI) tools become widely accessible, more patients and medical professionals will turn to them for medical information. Large language models (LLMs), a subset of AI, excel...
3.
Zhao S, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, et al.
Nat Genet
. 2024 Jul;
56(8):1689-1700.
PMID: 39020220
The impact of variations in the three-dimensional structure of the genome has been recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep Hi-C sequencing with matched...
4.
Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski N, et al.
bioRxiv
. 2024 Jun;
PMID: 38895460
Background: Prostate cancer is a heterogenous disease, but once it becomes metastatic it eventually becomes treatment resistant. One mechanism of resistance to AR-targeting therapy is lineage plasticity, where the tumor...
5.
Rydzewski N, Shi Y, Li C, Chrostek M, Bakhtiar H, Helzer K, et al.
Commun Biol
. 2024 Mar;
7(1):314.
PMID: 38480799
Histopathologic diagnosis and classification of cancer plays a critical role in guiding treatment. Advances in next-generation sequencing have ushered in new complementary molecular frameworks. However, existing approaches do not independently...
6.
Patel K, Rydzewski N, Schott E, Cooley-Zgela T, Ning H, Cheng J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Mar;
119(5):1471-1480.
PMID: 38428681
Purpose: NCT03253744 is a phase 1 trial with the primary objective to identify the maximum tolerated dose (MTD) of salvage stereotactic body radiation therapy (SBRT) in patients with local prostate...
7.
Patel K, Rydzewski N, Schott E, Cooley-Zgela T, Ning H, Cheng J, et al.
Pract Radiat Oncol
. 2023 Jul;
13(6):540-550.
PMID: 37442430
Purpose: NCT03253744 was a phase 1 trial to identify the maximum tolerated dose (MTD) of image-guided, focal, salvage stereotactic body radiation therapy (SBRT) for patients with locally radiorecurrent prostate cancer....
8.
Rydzewski N, Helzer K, Bootsma M, Shi Y, Bakhtiar H, Sjostrom M, et al.
Semin Radiat Oncol
. 2023 Jun;
33(3):243-251.
PMID: 37331779
Developing radiation tumor biomarkers that can guide personalized radiotherapy clinical decision making is a critical goal in the effort towards precision cancer medicine. High-throughput molecular assays paired with modern computational...
9.
Sperger J, Helzer K, Stahlfeld C, Jiang D, Singh A, Kaufmann K, et al.
Clin Cancer Res
. 2023 Mar;
29(12):2324-2335.
PMID: 36939530
Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane...
10.
Feng E, Rydzewski N, Zhang M, Lundberg A, Bootsma M, Helzer K, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5396-5404.
PMID: 36260524
Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts....